DOW JONES28,992.41-227.57 -0.78%
S&P 5003,337.75-35.48 -1.05%
NASDAQ9,576.59-174.38 -1.79%

Goldman Sachs Upgrades Denali Therapeutics to Buy, Raises Price Target to $37

Goldman Sachs analyst Salveen Richter upgrades Denali Therapeutics (NASDAQ:DNLI) from Neutral to Buy and raises the price target from $20 to $37.

Benzinga · 01/27/2020 11:03

Goldman Sachs analyst Salveen Richter upgrades Denali Therapeutics (NASDAQ:DNLI) from Neutral to Buy and raises the price target from $20 to $37.